Recurrent Malignant Glioma - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Recurrent Malignant Glioma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Recurrent Malignant Glioma - Pipeline Review, H1 2015', provides an overview of the Recurrent Malignant Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Recurrent Malignant Glioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Recurrent Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Recurrent Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Recurrent Malignant Glioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Recurrent Malignant Glioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Recurrent Malignant Glioma Overview 6
Therapeutics Development 7
Pipeline Products for Recurrent Malignant Glioma - Overview 7
Pipeline Products for Recurrent Malignant Glioma - Comparative Analysis 8
Recurrent Malignant Glioma - Therapeutics under Development by Companies 9
Recurrent Malignant Glioma - Therapeutics under Investigation by Universities/Institutes 10
Recurrent Malignant Glioma - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Recurrent Malignant Glioma - Products under Development by Companies 13
Recurrent Malignant Glioma - Products under Investigation by Universities/Institutes 14
Recurrent Malignant Glioma - Companies Involved in Therapeutics Development 15
Amgen Inc. 15
AstraZeneca PLC 16
Eisai Co., Ltd. 17
Nerviano Medical Sciences S.r.l. 18
Sanofi 19
Recurrent Malignant Glioma - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
cabazitaxel - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Carboxyamidotriazole Orotate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
carmustine SR - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cell Therapy for Refractory Gliomas - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cell Therapy to Target IL-13 for Malignant Glioma - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Dendritic Cell Therapy for Metastatic Melanoma and Recurrent Malignant Glioma - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Dendritic Cell Therapy for Oncology - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
disufenton sodium - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DNX-2401 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lenvatinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
milciclib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
rilotumumab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Recurrent Malignant Glioma - Recent Pipeline Updates 51
Recurrent Malignant Glioma - Dormant Projects 56
Recurrent Malignant Glioma - Discontinued Products 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products under Development for Recurrent Malignant Glioma, H1 2015 7
Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Recurrent Malignant Glioma - Pipeline by Amgen Inc., H1 2015 15
Recurrent Malignant Glioma - Pipeline by AstraZeneca PLC, H1 2015 16
Recurrent Malignant Glioma - Pipeline by Eisai Co., Ltd., H1 2015 17
Recurrent Malignant Glioma - Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 18
Recurrent Malignant Glioma - Pipeline by Sanofi, H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Recurrent Malignant Glioma Therapeutics - Recent Pipeline Updates, H1 2015 51
Recurrent Malignant Glioma - Dormant Projects, H1 2015 56
Recurrent Malignant Glioma - Discontinued Products, H1 2015 57